Evento
Circulating miRNAs as potential biomarkers for the early diagnosis of prostate cancer
Duca, Rocío Belén
; Farré, Paula Lucía
; Graña, Karen Daniela; Massillo, Cintia Lorena
; Garcia, Nicolas; Dimase, Federico; Gandini, Norberto Ariel
; Dalton, Guillermo Nicolás
; de Siervi, Adriana
Tipo del evento:
Reunión
Nombre del evento:
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimenta; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Fecha del evento:
13/11/2019
Institución Organizadora:
Sociedad Argentina de Investigación Clínica;
Asociación Argentina de Farmacología Experimental;
Sociedad Argentina de Biología;
Sociedad Argentina de Protozoología;
Asociación Argentina de Nanomedicinas;
Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio;
The Histochemical Society;
Título de la revista:
Medicina (Buenos Aires)
Editorial:
Fundación Revista Medicina
ISSN:
0025-7680
e-ISSN:
1669-9106
Idioma:
Inglés
Clasificación temática:
Resumen
.Prostate cancer (PCa) is the most common type of cancer and the third cause of death by cancer in Argentinian men. miRNAs are small non-coding RNA molecules that regulate gene expression. miRNAs can be secreted by tumor cells and circulate in the bloodstream. Our aim was to identify circulating miRNAs as candidate biomarkers for the diagnosis of PCa. GeneChip® miRNA 4.0 Arrays (Affymetrix) were hybridized with circulating RNA obtained from serum of PCa patients or healthy donors. Diagnosed PCa patients, free of treatment, were divided into subcategories according to Gleason grade. After data normalization, we identified a list of miRNAs (miR-4668-5p, miR 2277-5p, miR-3613-3p, miR-101-3p, miR-320e-5p, miR-6750- 5p, miR-548x-3p, miR-320a, miR-4532, miR-21-5p) that were increased in PCa patients serum compared to healthy donors. To validate these results, NSG mice were inoculated s.c. with PC3 or 22Rv1 PCa cell lines. After tumor growth, mice with tumors and a non-tumor mice group (control) were sacrificed. Blood and tumor samples were collected for RNA isolation. miRNA expression levels were assessed by stem-loop RT-qPCR. miR-4668-5p, miR 2277-5p, miR-3613-3p and miR-21-5p were significantly increased in the circulation of mice inoculated with PC3 cells compared to control. Also, miR-101-3p and miR-3613-3p were significantly upregulated in the plasma of mice that were inoculated with 22Rv1 compared to control. miR-2277-5p was not detected in the plasma of 22Rv1 injected mice. Interestingly, miR-101-3p was increased in circulation of 22Rv1 compared to PC3 injected mice, while miR-4668-5p was increased in plasma of PC3 compared to 22Rv1 injected mice. Additionally, miR-101- 3p was upregulated in 22Rv1 compared to PC3 xenografts. In summary, our work defines novel candidate biomarkers for PCa diagnosis based on circulating miRNAs from human serum samples. These biomarkers were also detected in xenografts and plasma from mice.
Palabras clave:
PROSTATE
,
CANCER
,
BIOMARKER
,
miRNAs
Archivos asociados
Licencia
Identificadores
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Eventos(INIBIBB)
Eventos de INST.DE INVEST.BIOQUIMICAS BAHIA BLANCA (I)
Eventos de INST.DE INVEST.BIOQUIMICAS BAHIA BLANCA (I)
Citación
Circulating miRNAs as potential biomarkers for the early diagnosis of prostate cancer; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimenta; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 147-147
Compartir